PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
168.96%
Revenue growth above 1.5x CVE's 7.76%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
2212.00%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
129.91%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
129.91%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
152.75%
Net income growth above 1.5x CVE's 5.99%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
152.11%
EPS growth above 1.5x CVE's 6.25%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
152.26%
Diluted EPS growth above 1.5x CVE's 6.25%. David Dodd would see if there's a robust moat protecting these shareholder gains.
1.40%
Share change of 1.40% while CVE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.99%
Diluted share change of 0.99% while CVE is zero. Bruce Berkowitz might see a minor difference that could widen over time.
16.55%
Maintaining or increasing dividends while CVE cut them. John Neff might see a strong edge in shareholder returns.
124.10%
OCF growth above 1.5x CVE's 51.22%. David Dodd would confirm a clear edge in underlying cash generation.
85.61%
FCF growth under 50% of CVE's 361.54%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-76.47%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-64.31%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-39.50%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-89.40%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-88.07%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-82.89%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-78.00%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
126.62%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
45.04%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-68.23%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-67.75%
Negative 5Y equity/share growth while CVE is at 11.21%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-0.97%
Negative 3Y equity/share growth while CVE is at 2.59%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-84.68%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-92.41%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-89.55%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
50.63%
Our AR growth while CVE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
-2.34%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
25.25%
Positive BV/share change while CVE is negative. John Neff sees a clear edge over a competitor losing equity.
-20.74%
We’re deleveraging while CVE stands at 0.85%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-3.93%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.